Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

In addition to dysregulated JAK/STAT signaling, activation of the AKT/mTOR pathway occurs in myelofibrosis, a myeloproliferative neoplasm with no approved therapies. We conducted a phase 1/2 study with everolimus, an mTOR inhibitor, in 39 high- or intermediate-risk primary or postpolycythemia vera/p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Guglielmelli, Paola, Barosi, Giovanni, Rambaldi, Alessandro, Marchioli, Roberto, Masciulli, Arianna, Tozzi, Lorenzo, Biamonte, Flavia, Bartalucci, Niccolò, Gattoni, Elisabetta, Lupo, Maria Letizia, Finazzi, Guido, Pancrazzi, Alessandro, Antonioli, Elisabetta, Susini, Maria Chiara, Pieri, Lisa, Malevolti, Elisa, Usala, Emilio, Occhini, Ubaldo, Grossi, Alberto, Caglio, Silvia, Paratore, Simona, Bosi, Alberto, Barbui, Tiziano, Vannucchi, Alessandro M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2011
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3365876/
https://ncbi.nlm.nih.gov/pubmed/21725052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-01-330563
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados